2 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Myeloma, Multiple: new trials by email Literature Review of Myeloma, Multiple trials Research Report on Myeloma, Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) Hematopoietic Stem Cell Transplantation (HSCT), Acute Myeloid Leukemia (AML) | Recruiting | Yigeng Cao,MD,PhD | 1000 | 2023-09-01 | 2025-10-03 | |
| Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM Lenalidomide, Ixazomib, Daratumumab Injection - Myeloma, Multiple | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 79 | 2020-10-21 | 2025-12-18 |
| Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma Avelumab, External beam radiotherapy - Myeloma, Multiple, Myeloma-Multiple | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2019-10-17 | 2021-05-12 |
| Fluciclovine PET/CT in Multiple Myeloma Patients Myeloma, Multiple, PET-CT | Recruiting | Oslo University Hospital | 10 | 2019-03-01 | 2019-05-30 | |
| CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma Treat Regimen - Myeloma, Multiple | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 18 | 2017-05-10 | 2020-02-24 |
| CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma CKD-581 - Myeloma, Multiple | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 18 | 2017-01-01 | 2020-02-24 |
| Study of the Immune Response After Vaccination in Multiple Myeloma Patients Multiple Myeloma, Myeloma, Multiple | Completed | Wake Forest University Health Sciences | 19 | 2014-12-30 | 2024-10-03 | |
| Comprehensive Frailty Assessment Myeloma, Multiple, Paraproteinemias | Completed | Ohio State University Comprehensive Cancer Center | 111 | 2014-04-01 | 2018-02-28 |
Multiple Myeloma (8) · Amyloidosis (1) · Anemia, Aplastic (1) · Hematologic Neoplasms (1) · Hemophilia A (1) · Hemostatic Disorders (1) · Influenza, Human (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Monoclonal Gammopathy of Undetermined Significance (1) · Myelodysplastic Syndromes (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Pneumonia (1)
Blood Protein Disorders (8) · Cardiovascular Diseases (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemorrhagic Disorders (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Vascular Diseases (8) · Hemostatic Disorders (7) · Neoplasms, Plasma Cell (7) · Paraproteinemias (7) · Anemia (1)
CKD-581 (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Lenalidomide (1) · avelumab (1) · daratumumab (1) · ixazomib (1)
Chong Kun Dang Pharmaceutical (2) · Alliance Foundation Trials, LLC. (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · Oslo University Hospital (1) · Wake Forest University Health Sciences (1) · Yigeng Cao,MD,PhD (1)
United States (4) · South Korea (2) · China (1) · Norway (1)
Andrew Yee, MD (1) · Ashley Rosko, MD (1) · Chanki Min (1) · Evanthia Galanis, MD (1) · Hui Geng (1) · Mark Roschewski, M.D. (1) · Michael Thompson, MD, PhD (1) · Min Ji Song (1)